Expanding HSA eligibility could pay for GLP-1s

Published 4 Min Read

Canisters of Ozempic GLP-1 medication
Bloomberg

  • Key Insight: Discover how expanded HSA eligibility could shift GLP‑1 costs into consumer-funded care.
  • What’s at Stake: Employers’ benefit budgets and access decisions face pressure from rising GLP‑1 costs.
  • Supporting Data: About $150 billion sits in roughly 50 million HSA accounts nationwide.
  • Source: Bullets generated by AI with editorial review

As employers face growing pressure to cover costly GLP-1s for weight loss, an expansion of health savings accounts (HSAs) may be the best hope to satisfy massive consumer demand for this emerging drug category. It’s also an opportunity to empower health plan members to shoulder financial responsibility in making this lifestyle choice, which squares with healthcare consumerism messaging over the past 25 years. 

Bruce Shutan
Contributing writer

Bruce Shutan is an Employee Benefit News contributing writer based in Portland, Oregon.


For reprint and licensing requests for this article, click here.


More From Employee Benefit News

Sign Up Form

Login Modal Form